SEEL(Delisted)
Seelos TherapeuticsยทNASDAQ
--
--(--)
SEEL Profile
Seelos Therapeutics, Inc.
A biopharmaceutical company focused on developing novel treatments for rare diseases and central nervous system disorders
300 Park Avenue, 2nd Floor, New York, NY 10022
--
Seelos Therapeutics, Inc., was incorporated in Nevada in 1987. The company and its affiliates have been present in the pharmaceutical industry since 1995. As a pharmaceutical company, it is focused on achieving efficient development of products to address significant unmet needs in central nervous system (" CNS ") diseases and rare diseases. The company's product development has leveraged NexACT's proprietary penetration enhancement technology. The company's initial product is Canadian-approved Vitaros for the treatment of erectile dysfunction; the latter online late-stage product candidate, Femprox, for the treatment of female sexual arousal disorder. The company has applied to Switzerland for decentralized approval, hoping that Vitaros can be used in Europe to treat ED. Femprox has completed Phase III clinical trials in China. The company is submitting more clinical trial regulatory plans to the US, Canada and Europe.
